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Two real-time polymerase chain reaction assays were developed to detect
mutations in codons 83 and 87 in gyrA and in codons 80 and 91 in parC, the main
sites that causes quinolone resistance in pathogenic Escherichia coli and Shigella
spp. isolates. These assays can be employed as a useful method for controlling
infections caused by quinolone-resistant E coli and Shigella isolates.1. Introduction
Fluoroquinolone is highly effective against enteric
Gram-negative bacteria [1]. Within a short period of
time, however, the widespread use of this drug has
resulted in the emergence of fluoroquinolone-resistant,
Gram-negative bacteria [2e4].ted under the terms of the C
0) which permits unrestrict
roperly cited.
ase Control and PreventionResistance to fluoroquinolones is mainly caused by
mutations in the quinolone-resistance determining
regions (QRDRs) of gyrA and parC, which encode the
GyrA and ParC proteins, respectively [5]. Most
quinolone-resistant isolates have at least one gyrA
mutation, and many have additional gyrA and/or parC
mutations [2,3]. Mutations in the gyrA amino acid
codons for Ser83 and/or Asp87 are commonly found inreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
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Targeted mutations are also frequently present in parC
in quinolone-resistant Gram-negative bacteria, including
mutations in the codons for Ser80, Glu84, and/or Arg91
[7,8]. Mutations in gyrA or parC have less of an effect
on resistance in Gram-negative bacteria by themselves
than they do when found in combination with other
mutations in these genes [9].
Currently, nucleotide sequencing is a common
method for the identification of mutations in the QRDRs
of gyrA and parC. Despite the widespread use of
sequencing, it is slow and expensive [10]. Various
alternative methods to replace sequencing have been
proposed, including polymerase chain reaction (PCR)-
restriction fragment length polymorphism (RFLP) [11],
real-time (RT)-based detection [12], and single-stranded
conformation polymorphism (SSCP) [13].
Our objective was to develop a quicker method for
the detection of quinolone resistance-related mutations
at the gyrA codons of Ser83 and Asp87 and the parC
codons of Ser80 and Arg91 in quinolone-resistant
Escherichia coli and Shigella spp. isolates. This tech-
nique is based on the detection of fluorescent emissions
from the PCR products of wild-type gyrA and parC;
isolates with mutations at specific sites in gyrA and parC
do not emit detectable fluorescence.2. Materials and Methods
The isolates used in this study are listed in Table 1.
Quinolone-resistant pathogenic E coli and Shigella spp.
isolates were obtained from the National Public Health
Network of Korea. Each isolate was identified according
to the Giraud method with some modifications [14].
Two multiplex PCR assays were developed to detect
mutations in the QRDRs of gyrA and parC. In the first
assay (named Gyr), Taqman MGB probes were designed
to detect wild-type nucleotide sequences corresponding
to the codons of Ser83 and Asp87 in gyrA; in the second
assay (named Par), probes were designed to detect wild-
type nucleotide sequences corresponding to the codons
of Ser80 and Agr87 in parC. Selective probes for both
assays were designed using Primer Express (version 3.0;
Applied Biosystems, Foster City, CA, USA) to detect
mutations in the second base of the each targeted codon.
Template DNA was prepared from each isolate by
boiling in 100 mL of 10 mM Tris-HCl (pH 8.0) for 10
minutes. The primers were synthesized by Bioneer
(Seoul, Korea), and the probes were synthesized by
Applied Biosystems. For each assay set, the probe for
one allele was labeled with FAM (6-carboxy-fluores-
cein) and the other was labeled with VIC (4,7,20-tri-
chloro-70-phenyl-6-carboxyfluorescein). The primers
and probes used in this study are shown in Table 2.
All of the PCR assays were used in a final volume of
20 mL that contained 5 mL of template DNA with0.2 mM of each primer, 0.5 mM of each probe, and 10 mL
of RT-PCR master mix (Kogen Biotech, Seoul, Korea).
All of the assays used the same thermocycling param-
eters. The reactions were performed in a LightCycler
480 system (Roche Diagnostics, Basel, Switzerland)
under the following conditions: one cycle of 50C for 5
minutes followed by 40 cycles of 95C for 15 seconds
and 60C for 1 minute.3. Results
After optimizing each assay, 14 Shigella spp. strains
with known mutations in gyrA and/or parC were tested
using the Gyr and Par assays. All of the known muta-
tions at Ser83 and Asp87 were successfully detected in
the gyrA mutants using the Gyr assay: 10 strains had
mutations at Ser83 and one strain had a mutation at both
Ser83 and Asp87. Additionally, all of the known
mutations in Ser80 and Arg87 were successfully detec-
ted in the parC mutants using the Par assays. We
assessed PCR amplification in all of the mutant isolates
(i.e., those that did not emit fluorescence). Amplification
of both the 78-base pair (bp) Gyr assay PCR product and
the 98-bp Par assay PCR product were confirmed in all
of the tested isolates using electrophoresis (data not
shown).
To determine the accuracies of the RT-PCR assays,
48 strains of quinolone-resistant pathogenic E coli and
14 S flexneri isolates were tested using both the Gyr
and Par assays. The fluorescent signals generated from
the RT-PCR Gyr and Par assays were analyzed to
determine the presence of mutations in gyrA and/or
parC. The PCR results were confirmed by sequencing.
All of the PCR results corresponded 100% with the
sequencing results (Table 1). Notably, in strain QR24,
a fluorescent signal was detected with the Par assay,
but sequencing revealed a mutation in parC codon
Ala81; however, this mutation at codon Ala81 did not
affect the PCR results.4. Discussion
Resistance to quinolone is caused by a variety of
mechanisms, such as a mutation in the targeted
enzyme’s coding sequence, participation of the efflux
system, and the actions of qnr [15]. Compared with
other quinolone-resistance mechanisms, the largest
contributing factor to resistance is alteration of the target
sequence. Thus, the fast, precise detection of mutations
in the QRDRs of the target enzymes is very important
for controlling infections caused by quinolone-resistant
strains [9].
The RT-PCR assay developed for this study can
simultaneously identify mutations in specific regions of
the gyrA and parC genes. Compared with similar PCR
Table 1. MIC and nucleotide changes in the QRDRs of the gyrA and parC genes of quinolone-resistant strains of Escherichia
coli and Shigella spp
Strain no. Species
MIC
RT-PCR assaya gyrA amino acid at codon parC amino acid at codon
CIPb
Gyr Par
83 87 80 91
83 87 80 91 TCG (Ser) GAC (Asp) TCG (Ser) CGA (Arg)
982962 S sonnei 1.0 - þ þ þ -T-(Leu) — — —
994263 S sonnei 0.125 - þ þ þ -T-(Leu) — — —
990379 S flexneri 0.25 - þ þ þ -T-(Leu) — — —
990036 S flexneri 0.5 þ þ þ - — — — -AG(Gln)
000207 S sonnei 0.25 - þ þ þ -T-(Leu) — — —
000784 S flexneri 0.125 - þ þ þ -T-(Leu) — — —
013008 S sonnei 0.25 - þ þ þ -T-(Leu) — — —
020065 S sonnei 0.25 - þ þ þ -T-(Leu) — — —
021586 S sonnei 0.5 þ þ þ - — — — -AG(Gln)
020369 S flexneri 0.5 - þ þ þ -T-(Leu) — — —
021787 S flexneri 16 - þ - - -T-(Leu) — G–(Ile) -AG(Gln)
021895 S flexneri 8 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
022149 S flexneri 0.5 þ þ þ - — — — -AG(Gln)
QR01 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR02 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR03 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR04 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG (Gln)
QR05 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR06 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR07 E coli 64 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR08 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR09 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR10 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR11 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR12 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR13 E coli 6 - þ - þ -T-(Leu) — G–(Ile) —
QR14 E coli 6 - þ - þ -T-(Leu) — G–(Ile) —
QR15 E coli 32 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR16 E coli 6 - þ - þ -T-(Leu) — G–(Ile) —
QR17 E coli 32 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR18 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR19 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR20 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR21 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR22 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR23 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR24 E coli 32 - þ þ þ -T-(Leu) — — —
QR25 E coli 128 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR26 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR27 E coli 8 - þ - þ -T-(Leu) — G–(Ile) —
QR28 E coli 6 - þ - þ -T-(Leu) — G–(Ile) —
QR29 E coli 256 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR30 E coli 8 - þ - þ -T-(Leu) — G–(Ile) —
QR31 E coli 256 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR32 E coli 128 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR33 E coli 256< - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR34 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR35 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR36 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR37 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR38 E coli 128 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
QR39 E coli 128 - - - þ -T-(Leu) -G-(Gly) G–(Ile) —
(Continued on next page )
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Table 1 (Continued )
Strain no. Species
MIC
RT-PCR assaya gyrA amino acid at codon parC amino acid at codon
CIPb
Gyr Par
83 87 80 91
83 87 80 91 TCG (Ser) GAC (Asp) TCG (Ser) CGA (Arg)
QR40 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR41 E coli 64 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
QR42 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR43 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR44 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
QR45 E coli 6 - þ - þ -T-(Leu) — G–(Ile) —
QR46 E coli 4 - þ - þ -T-(Leu) — G–(Ile) —
QR47 E coli 3 - þ - þ -T-(Leu) — G–(Ile) —
QR48 E coli 32 - þ - þ -T-(Leu) — G–(Ile) —
100020 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100053 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100054 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100377 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100378 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100379 S flexneri 4 - - - - -T-(Leu) A–(Gly) G–(Ile) -AG(Gln)
100449 S flexneri 16 - - - - -T-(Leu) A–(Gly) G–(Ile) -AG(Gln)
100781 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100782 S flexneri 16 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
100985 S flexneri 16 - - - - -T-(Leu) A–(Gly) G–(Ile) -AG(Gln)
101464 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
102724 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
102725 S flexneri 4 - - - - -T-(Leu) -G-(Gly) G–(Ile) -AG(Gln)
102726 S flexneri 4 - - - - -T-(Leu) A–(Gly) G–(Ile) -AG(Gln)
aþ, emitted fluorescenc; bCIP, Ciprofloxacin; -, did not emit fluorescence.
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that can only identify one or two mutated sites in gyrA
and parC, this RT-PCR assay is relatively simple and
fast.
In the accuracy test for quinolone-resistant S flexneri
isolates, this assay detected different types of mutations
at gyrA codon 87. In 10 strains, the codon was mutated
from aspartic acid (GAC) to glycine (GGC); in the other
four strains, the codon was mutated to asparagine
(AAC). This assay was designed to detect mutations in
the second base pair of each targeted codon, but it alsoTable 2. Primer and probe sequences for the SNPs tests
Target gene Primer
gyrA Detection primer F
Detection primer R
SNP 83 detection probe (FAM)
SNP 87 detection probe (VIC)
parC Detection primer F
Detection primer R
SNP 80 detection probe (FAM)
SNP 91 detection probe (VIC)detected mutations in the first base pair of the targeted
codon. Therefore, the Par assay can also be influenced
by silent mutations in the target site.
This assay cannot identify mutations outside of the
four target sites (codons 83 and 87 in gyrA and codons
81 and 90 in parC ). Also, it cannot identify mutations in
gyrB or parE. However, most mutations that influence
quinolone resistance usually include one or more of
these four target sites. Identification of mutations at
these four target sites is sufficient to explain the resis-
tance mechanism of quinolone-resistant isolates.Sequence (5’/3’)
TGGTGACGTAATCGGTAAATACCA
GAATGGCTGCGCCATACG
FAM-TGACTCGGCGGTTT- MGBNF
VIC-ACGATAGTGTCATAAAC-MGBNF
GACGTACTGGGTAAATACCATCCG
TCAACCAGCGGATAACGGTAA
FAM-GCGATAGCACCTGT-MGBNFQ
VIC-AGAACGGTCGCGCC-MGBNFQ
Detection of gyrA and parC Mutations 117In conclusion, we developed a simple and efficient
RT-PCR assay that simultaneously detects themajor gyrA
and parC mutations related to quinolone resistance. This
assay can be easily applied to laboratory-based surveil-
lance systems as a substitutemethod forDNA sequencing.
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